Protein-Based COVID-19 Vaccines: A New Era of Vaccination | Novavax Inc. – Medriva

A New Era of Vaccination: Protein-Based COVID-19 Vaccines

The COVID-19 pandemic has stressed the significance of vaccines in the global fight against infectious diseases. In response, Novavax Inc., a leading biotechnology company, has developed an innovative protein-based COVID-19 vaccine, Nuvaxovid XBB 1.5, which has now been authorized for use in Canada, the United States, the European Union, and by the World Health Organization, for individuals aged 12 years and older.

The protein-based vaccine platform has been recognized for its proven safety record, having been used in several vaccine formulas over the years. Dr. Walker, a renowned health expert, has underscored the significant safety track record of these vaccines, emphasizing their importance in the fight against COVID-19.

Protein-based vaccines, unlike mRNA vaccines, use harmless pieces of the virus to trigger an immune response and build immunity. Novavaxs vaccine stimulates both arms of the immune system and incites functional immune responses against various COVID-19 variants. Furthermore, it utilizes Novavaxs patented Matrix M adjuvant, which boosts the immune system response, making it broader and more durable.

Common side effects of Novavaxs vaccine include headache, nausea, muscle pain, and fatigue. However, these are temporary and typically resolve within a few days. The vaccine is a ready-to-use liquid formulation and is stored at a temperature of 2 to 8C, making it a practical choice for mass vaccination programs worldwide.

While protein-based vaccines have proven their efficacy and safety, the introduction of RNA-based vaccines has marked a significant advancement in vaccine development. The newly authorized ARCT-154, an RNA-based COVID-19 vaccine authorized in Japan, uses a form of RNA capable of self-replication inside cells, providing a potent defense against various infectious diseases and cancers.

Despite the potential advantages of RNA-based vaccines, they come with their own set of challenges. The longer sequences in self-amplifying RNA (saRNA) vaccines add complexity to the manufacturing process, and the intricacies of interacting with the immune system pose challenges. On the other hand, protein-based vaccines, such as Novavaxs, have a more established safety record and are relatively simpler to produce.

The development of nucleocapsid (N) protein-based COVID-19 vaccines is an exciting area of research. These vaccines target the N sequences of the virus, which are prone to mutation, and could potentially lead to the development of broad-spectrum vaccines. However, the mutability of N sequences also presents challenges, particularly in terms of the development of cross-reactive vaccines due to escape mutations.

As we continue to battle the COVID-19 pandemic, the importance of vaccination cannot be overstated. Whether you opt for a protein-based or RNA-based vaccine, getting vaccinated is crucial to protect not only yourself but also those around you, particularly as we prepare for the winter season and the potential resurgence of respiratory illnesses.

View original post here:

Protein-Based COVID-19 Vaccines: A New Era of Vaccination | Novavax Inc. - Medriva